Skip to main content
. 2011 Mar;178(3):1340–1349. doi: 10.1016/j.ajpath.2010.11.058

Figure 6.

Figure 6

Blockade of CXCL5 or CXCR2 attenuated human pancreatic cancer growth. A: CXCL5 siRNA intratumoral treatment slowed MIA PaCa-2 cell growth in nude mice. Mice with intratumoral injection of CXCL5 (squares) or control (circles) siRNA were monitored for tumor growth twice weekly. Values are mean ± SD tumor volume. B: Antiserum to CXCR2 decreased BxPC3 cancer cell growth in nude mice. Mice were treated with antiserum to CXCR2 or control serum (i.p. injection) daily for 6 weeks. Values are mean ± SD tumor volume. C: CXCR2 antiserum treatment impaired angiogenesis in nude mice. Tumors from CXCR2 antiserum–treated or control mice were stained with antibody to CD31. The MVD was determined by counting blood vessels with positive CD31 staining. Horizontal bars indicate mean MVD. *P < 0.05.